MA47793A - Nouvelle dispersion amorphe d'hydrazide n'- (2-chloro-6-méthyl-benzoyl) d'acide 4-méthyl-3-quinoline-3-yléthynyle-benzoïque - Google Patents

Nouvelle dispersion amorphe d'hydrazide n'- (2-chloro-6-méthyl-benzoyl) d'acide 4-méthyl-3-quinoline-3-yléthynyle-benzoïque

Info

Publication number
MA47793A
MA47793A MA047793A MA47793A MA47793A MA 47793 A MA47793 A MA 47793A MA 047793 A MA047793 A MA 047793A MA 47793 A MA47793 A MA 47793A MA 47793 A MA47793 A MA 47793A
Authority
MA
Morocco
Prior art keywords
methyl
ylethynyl
hydrazide
quinoline
benzoyl
Prior art date
Application number
MA047793A
Other languages
English (en)
Inventor
Nitin Dharmadhikari
Bramhanand Hanamannavar
Yashoraj Zala
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of MA47793A publication Critical patent/MA47793A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA047793A 2017-03-15 2018-03-15 Nouvelle dispersion amorphe d'hydrazide n'- (2-chloro-6-méthyl-benzoyl) d'acide 4-méthyl-3-quinoline-3-yléthynyle-benzoïque MA47793A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201721005414 2017-03-15

Publications (1)

Publication Number Publication Date
MA47793A true MA47793A (fr) 2020-01-22

Family

ID=63521897

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047793A MA47793A (fr) 2017-03-15 2018-03-15 Nouvelle dispersion amorphe d'hydrazide n'- (2-chloro-6-méthyl-benzoyl) d'acide 4-méthyl-3-quinoline-3-yléthynyle-benzoïque

Country Status (8)

Country Link
US (2) US11351123B2 (fr)
EP (1) EP3596050A4 (fr)
JP (2) JP7234129B2 (fr)
CN (1) CN110494422A (fr)
AU (1) AU2018235446B2 (fr)
CA (1) CA3056348A1 (fr)
MA (1) MA47793A (fr)
WO (1) WO2018167802A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2911040C (fr) 2012-05-02 2021-11-16 Georgetown University Traitement d'une synucleinopathie au moyen d'inhibiteurs de la tyrosine kinase
AU2021317186A1 (en) * 2020-07-31 2023-03-16 Sun Pharma Advanced Research Company Limited N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide for treatment of Alzheimer's Disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2495016T1 (sl) * 2005-12-23 2020-04-30 Ariad Pharmaceuticals, Inc. Biciklične heteroarilne spojine
AU2007249924B2 (en) * 2006-05-08 2013-07-04 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
WO2008055966A1 (fr) 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Forme de dosage pharmaceutique pour l'administration orale d'un inhibiteur de la tyrosine kinase
JP5905028B2 (ja) 2011-01-21 2016-04-20 スン プハルマ アドバンセド リサーチ カンパニー リミテド ジアリールアセチレンヒドラジドを含有するチロシンキナーゼ阻害剤
WO2013105894A1 (fr) 2012-01-13 2013-07-18 Xspray Microparticles Ab Procédé de production de nanoparticules hybrides amorphes stables comprenant au moins un inhibiteur de la protéine kinase et au moins un constituant polymère stabilisant et matriciel
CN105744847A (zh) * 2013-11-15 2016-07-06 帝斯曼知识产权资产管理有限公司 通过热熔挤出获得的略溶化合物的制剂
EP2913048A1 (fr) 2014-02-27 2015-09-02 ratiopharm GmbH Composition pharmaceutique comprenant de la trametinib
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
TWI803187B (zh) 2014-08-08 2023-05-21 日商中外製藥股份有限公司 包含4環性化合物的非晶質體之固體分散體及製劑
US20170360791A1 (en) * 2014-12-04 2017-12-21 Astex Pharmaceuticals, Inc. Pharmaceutical compositions for increasing the bioavailability of poorly soluble drugs

Also Published As

Publication number Publication date
WO2018167802A1 (fr) 2018-09-20
RU2019132068A (ru) 2021-04-15
JP2020510066A (ja) 2020-04-02
AU2018235446B2 (en) 2022-04-07
EP3596050A4 (fr) 2021-01-13
CA3056348A1 (fr) 2018-09-20
JP7234129B2 (ja) 2023-03-07
US11351123B2 (en) 2022-06-07
AU2018235446A1 (en) 2019-10-03
CN110494422A (zh) 2019-11-22
US20210267906A1 (en) 2021-09-02
US20200085751A1 (en) 2020-03-19
EP3596050A1 (fr) 2020-01-22
JP2023027309A (ja) 2023-03-01
RU2019132068A3 (fr) 2021-06-22
WO2018167802A9 (fr) 2019-02-07

Similar Documents

Publication Publication Date Title
CO2017011535A2 (es) Composiciones de ácido obeticólico y métodos de uso
DK3606909T3 (da) Natriumsalt af n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1h-pyrazol-3-sulfonamid
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA49039A (fr) Nouvelles molécules bispécifiques de liaison à l'antigène capables de se lier spécifiquement à cd40 et à fap
MA46196A (fr) Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal
MA44725A (fr) Formulations d'un inhibiteur de lsd1
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
ECSP16093323A (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
DK3265084T3 (da) Farmaceutiske formuleringer af Bruton's tyrosinkinase-hæmmer
MA40775A (fr) Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38
MA47179A (fr) Composition d'acide dicarboxylique mannuronique
MA49847A (fr) Production enzymatique d'hexoses
MA46180A (fr) Analogues de l'amyline
DK3386991T3 (da) Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase
MA47494A (fr) Nouvelles utilisations d'anticorps anti-sirpg
IT201700081449A1 (it) Procedimento di purificazione dell'acido ialuronico
MA45917A (fr) Sulfonamides en tant qu'agonistes de gpr40 et gpr120
MA45987A (fr) Agonistes des récepteurs 5-ht2c, compositions et méthodes d'utilisation
MA42509A (fr) Formes d'adipate et compositions d'inhibiteurs de biaryle de la tyrosine kinase de bruton
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
MA44862A (fr) Formulations de fulvestrant et méthodes d'utilisation de celles-ci
CL2019002729A1 (es) Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico.
MA47793A (fr) Nouvelle dispersion amorphe d'hydrazide n'- (2-chloro-6-méthyl-benzoyl) d'acide 4-méthyl-3-quinoline-3-yléthynyle-benzoïque
MA53466A (fr) Formulation stable d'anticorps anti-osmr
DK4132915T3 (da) Substituerede isophtalsyrediamider